Abstract

Major Depressive Disorder (MDD) poses a significant global health burden, necessitating ingenious therapeutic approaches. MDD is associated with dysregulation in inflammatory pathways, making it a promising target for novel treatments alternatives to antidepressants . For years, the primary focus of antidepressant therapy has been to pump up the levels of monoamine neurotransmitters in the synaptic cleft.[1] Even so this selective target on monoaminergic transmission is not effective for all patients. Depressive symptoms have also shown to reoccur in patients post to discontinuing antidepressants.[7] Previous researches have evaluated that 1 out of 4 patients with MDD are affected with neuroinflammation which is linked with treatment resistance, and reduced health-related quality of life.[1]This review explores a novel avenue in MDD treatment by targeting the YY1-NF-κB inflammatory pathway which is involved in the pathophysiology of MDD.[2] The molecular docking study of Yin-Yang 1 or YY1(1UBD) with Ricinoleic Acid (RA) reveals a favorable and stable interaction. The findings demonstrate that Ricinoleic acid may inhibits YY1-mediated transcriptional activity by directly binding to the YY1 transcription factor in the inflammatory pathway so it may fail to further regulate the expression of interleukin-6 (IL-6), and interleukin-1β (IL-1β) which are major Pro-inflammatory cytokines, which play crucial role in inflammation. Blocking the activity of YY1 with Ricinoleic acid presents a novel therapeutic approach for MDD. ADME/T analysis further explored the potential of Ricinoleic acid as a novel therapeutic agent for treatment of MDD .We discuss the theoretical foundations, potential advantages over traditional antidepressants, and the need for further exploration through experimental validation and clinical studies.